CLM SAP Edition 14 Evaluation and Management of Familial Hypercholesterolemia


CLM SAP Edition 14 Evaluation and Management of Familial Hypercholesterolemia

Topic: Cardiology
Relevant Terms: Familial Hypercholesterolemia
Primary Audience: Nurse Practitioners, Pharmacists, Physician Assistants, physicians, registered dietitians, Registered Nurses
Launch Date: 15-Jul-12
Credits: AMA PRA Category 1 Credits
3 ACPE contact hours
3 ANCC contact hours
3 CDR continuing professional education units
Expiration Date: The accreditation for this activity has expired.

Learning Objectives

After completing this activity, the participant will demonstrate the ability to:

  1. Describe the prevalence and associated risk of familial hypercholesterolemia, in order to increase awareness and understanding of the disease;
  2. Illustrate the importance of universal screening during childhood and cascade lipid screening of family members of known FH patients;
  3. Differentiate management strategies that improve the care of patients with FH and reduce their elevated risk of CHD;
  4. Evaluate the clinical effects, safety and efficacy data for current and new treatment options for FH patients;
  5. Implement evidence-based treatment options for screening, diagnosing and treating FH in both pediatric and adult patients (including women of childbearing potential and during pregnancy).


    See Faculty section below for a complete list of faculty.
    Criteria for Success
    Statements of credit will be awarded based on the participant's attendance and submission of the activity evaluation form. No partial credit awarded for ACPE credit. A statement of credit will be available for download upon completion of the online evaluation/claimed credit form. In order to receive credit, participants should complete the online course, score at least 30% on the post-test, and submit the evaluation. If you have questions about this CME/CE activity, please contact the NLA at

    The National Lipid Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The National Lipid Association designates this enduring activity for a maximum of 3.0 AMA PRA Category 1 Credits™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

    Physician Assistants
    NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by ACCME.
    ©2011 National Lipid Association Complex Lipid Management Self-Assessment Program, Edition 14 5

    CE credit provided by AKH Inc., Advancing Knowledge in Healthcare

    AKH Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This application-based activity is approved for 3.0 contact hours (0.3 CEUs) UAN 0077-9999-12-025-H04-P. Initial release date July 15, 2012.

    AKH Inc. is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's COA.
    AKH Inc. designates this educational activity for 3.0 contact hours (0.3 CEUs). Accreditation applies solely to educational activities and does not imply approval or endorsement of any commercial product by the ANCC-COA.

    AKH Inc. is a Continuing Professional Education (CPE) Accredited Provider with the Commission on Dietetic Registration (CDR). Registered dietitians (RDs) and dietetic technicians, registered (DTRs) will receive 3.0 continuing professional education units (CPEUs) for completion of this program/material. CDR Accredited Provider #AN008. The focus of this activity is rated Level 2. Learners may submit evaluations of program/materials quality to the CDR at

    Disclosure of Unlabeled Use and Investigational Product
    This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

    Program Editors and Faculty
    Michael H. Davidson, MD, FACC, FACP, FNLA*
    Clinical Professor
    Director of Preventive Cardiology
    The University of Chicago Pritzker School of Medicine
    Chicago, IL
    Anne C. Goldberg, MD, FACP, FAHA, FNLA*
    Associate Professor of Medicine
    Washington University School of Medicine
    St. Louis, MO
    Dante S. LaRocca, PhD
    Professional Evaluation, Inc. (PEI)
    Mary P. McGowan, MD, FNLA*
    Executive Director
    Phase 1-4 Clinics
    Cincinnati, OH
    Patrick M. Moriarty, MD, FACP, FACC
    Professor of Medicine
    Director of Clinical Pharmacology
    University of Kansas Medical Center
    Kansas City, KS
    *Diplomate American Board of Clinical Lipidology

    Faculty Disclosures
    Michael H. Davidson, MD
    Advisory Board /Consultant
    Abbott Laboratories, Inc.; Aegerion Pharmaceuticals, Inc.; Amgen.; AstraZeneca; Atherotech; Daiichi-Sankyo Inc.; DTC MD (Direct To Consumer); Esperion Therapeutics, Inc.;  GlaxoSmithKline; iMD (Intelligent Medical Decisions); KineMed, Inc.; LipoScience, Inc.; Merck & Co, Inc..; Novo Nordisk; Roche; sanofi-aventis; Synarc, Inc.; Takeda Pharmaceuticals
    North America, Inc.
    Equity/Board of Directors
    DTC MD (Direct To Consumer); Omthera Pharmaceuticals, Inc.;
    SonoGene, LLC
    Abbott Laboratories, Inc.; Daiichi-Sankyo, Inc.; GlaxoSmithKline;
    Merck & Co, Inc.; Roche
    Speaker Bureau
    Abbott Laboratories, Inc.; AstraZeneca; GlaxoSmithKline; Merck & Co, Inc.

    Anne C. Goldberg, MD
    Roche/Genentech; ISIS-Genzyme; Merck & Co.
    Amarin; Abbott Laboratories; GlaxoSmithKline; ISIS-Genzyme Corporation; Merck & Co.; Novartis; Regeneron

    Dante S. LaRocca, PhD
    Nothing to disclose
    Mary P. McGowan, MD
    Abbott Laboratories, Inc.; Genzyme
    Speaker Bureau
    Genzyme; GlaxoSmithKline; Merck/Schering-Plough Pharmaceuticals, Inc.

    Patrick M. Moriarty, MD
    B. Braun Medical, Inc.
    Abbott Laboratories, Inc.; AstraZeneca; B. Braun Medical, Inc.;
    Genzyme; Kaneka Pharma America LLC; Regeneron Pharmaceuticals, Inc.; sanofi-aventis
    Speaker Bureau
    Abbott Laboratories, Inc.; Merck & Co, Inc.
    Nothing to disclose
    Nothing to disclose

    All materials provided in the self-assessment activity are presented as is without warranty or guarantee for fitness of use for your specific purpose. This activity is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The activity serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. NLA, AKH Inc., the author(s) and the publisher specifically disclaim responsibility for any adverse consequences resulting directly or indirectly from information in the activity, for undetected error, or through reader's misunderstanding of the content.

    Disclosure Declaration
    It is the policy of NLA and AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The faculty must disclose to the participants any significant relationships with commercial interests whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflict of interest is resolved by NLA and AKH prior to accreditation of the activity. NLA and AKH planners and reviewers have no relevant financial relationships to disclose.

    System Requirements
    To view this educational activity you will need one of the following web browsers: Google Chrome for Windows, Mac, or Linux; Internet Explorer 7.0+ for Windows; Mozilla 1.4+ for Windows, Mac, or Linux; Firefox 3.5+ for Windows, Mac, or Linux; or Safari 4.0+ for Mac.